PTC THERAPEUTICS, INC. — Director's Dealing 2015

May 20, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2015-05-15

Reporting Person: SCHMERTZLER MICHAEL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-05-15	Common Stock	J	733	—	Disposed	2988	Indirect
2015-05-18	Common Stock	J	2852	—	Disposed	136	Indirect
2015-05-19	Common Stock	J	136	—	Disposed	0	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	26766	Direct
Common Stock	1320369	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$51	2025-01-01	Common Stock (24000)	24000	Direct
Stock Option (Right to Buy)	$27.05	2024-01-27	Common Stock (20000)	20000	Direct
Stock Option (Right to Buy)	$10.85	2023-05-15	Common Stock (60000)	60000	Direct
Stock Option (Right to Buy)	$218.4	2022-01-10	Common Stock (276)	276	Direct
Stock Option (Right to Buy)	$490.8	2021-04-27	Common Stock (276)	276	Direct
Stock Option (Right to Buy)	$1149.6	2020-02-02	Common Stock (216)	216	Direct
Stock Option (Right to Buy)	$508.8	2019-10-07	Common Stock (266)	266	Direct
Stock Option (Right to Buy)	$735.6	2018-01-25	Common Stock (166)	166	Direct
Stock Option (Right to Buy)	$735.6	2018-07-14	Common Stock (83)	83	Direct
Stock Option (Right to Buy)	$626.4	2017-04-18	Common Stock (125)	125	Direct
Stock Option (Right to Buy)	$392.4	2016-03-01	Common Stock (90)	90	Direct

Footnotes

F1: Represents 26,766 shares of common stock of the Issuer ("common stock") directly held by the reporting person.

F2: Represents dispositions pursuant to Rule 144 of (i) 687 shares of common stock held by EMA Private Equity Fund 1999 LP and (ii) 46 shares of common stock held by Credit Suisse First Boston Finders and Screeners LP at a weighted average price of $52.8576 per share. Although included in the reporting person's prior ownership reports, the reporting person disclaims beneficial ownership of the disposed securities.

F3: Consists of (i) 2,800 shares held by EMA Private Equity Fund 1999 LP and (ii) 188 shares held by Credit Suisse First Boston Finders and Screeners LP. The reporting person is a managing director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P. The reporting person disclaims beneficial ownership of the shares of common stock held by these entities.

F4: Represents dispositions pursuant to Rule 144 of (i) 2,673 shares of common stock held by EMA Private Equity Fund 1999 LP and (ii) 179 shares of common stock held by Credit Suisse First Boston Finders and Screeners LP at a weighted average price of $53.1517 per share. Although included in the reporting person's prior ownership reports, the reporting person disclaims beneficial ownership of the disposed securities.

F5: Consists of (i) 127 shares held by EMA Private Equity Fund 1999 LP and (ii) 9 shares held by Credit Suisse First Boston Finders and Screeners LP. The reporting person disclaims beneficial ownership of the shares of common stock held by these entities.

F6: Represents dispositions pursuant to Rule 144 of (i) 127 shares of common stock held by EMA Private Equity Fund 1999 LP and (ii) 9 shares of common stock held by Credit Suisse First Boston Finders and Screeners LP at a weighted average price of $51.9676 per share. Although included in the reporting person's prior ownership reports, the reporting person disclaims beneficial ownership of the disposed securities.

F7: Represents shares of common stock held by Section Six Partners, L.P. The reporting person is a general and limited partner of, and trustee of certain family trusts holding interests in, Section Six Partners, L.P. The reporting person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein.

F8: This option was granted on May 15, 2013 and vests over three years, with 8.33% of the shares underlying the option vested on August 15, 2013 and an additional 8.33% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter.

F9: Currently exercisable.